LLY Jan 2024 510.000 call
| Previous close | 61.80 |
| Open | 63.54 |
| Bid | 62.80 |
| Ask | 65.95 |
| Strike | 510.00 |
| Expiry date | 2024-01-19 |
| Day's range | 63.54 - 63.54 |
| Contract range | N/A |
| Volume | |
| Open interest | 115 |
Motley Fool3 Magnificent Growth Stocks to Buy Right Now
Three Fool.com contributors believe they've identified truly magnificent growth stocks to buy right now. Here's why they chose AstraZeneca (NASDAQ: AZN), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (AstraZeneca): What makes AstraZeneca a magnificent long-term investment is how broad the business is and the potential it has to generate long-term gains.
BloombergObesity Drug Market Set to Hit $100 Billion by 2035, BMO Says
(Bloomberg) -- The global market for novel weight-loss drugs like Novo Nordisk A/S’s Ozempic and Wegovy is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications.Most Read from BloombergChinese Gold Buying Is Driving a Paradigm Shift in BullionWells Fargo Preps for Wealth Battle After $1 Billion TurnaroundUS to Keep a Distance From India-Canada Dispute, Signum’s Myers SaysBond Market Faces Quandary After Fed Signals It’s Almost DoneStocks Flash Reces
Motley FoolAre Wall Street Analysts Wrong About Eli Lilly Stock?
Based on analysts' projections, you might think the pharmaceutical giant isn't worth investing in right now.
